SV2006001916A - Formulaciones farmaceuticas transdermales - Google Patents

Formulaciones farmaceuticas transdermales

Info

Publication number
SV2006001916A
SV2006001916A SV2004001916A SV2004001916A SV2006001916A SV 2006001916 A SV2006001916 A SV 2006001916A SV 2004001916 A SV2004001916 A SV 2004001916A SV 2004001916 A SV2004001916 A SV 2004001916A SV 2006001916 A SV2006001916 A SV 2006001916A
Authority
SV
El Salvador
Prior art keywords
formulations
active agent
pharmaceutical formulations
skin
administration
Prior art date
Application number
SV2004001916A
Other languages
English (en)
Inventor
Amar Lulla
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of SV2006001916A publication Critical patent/SV2006001916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PROPORCIONAN FORMULACIONES TRANSDERMICAS PARA PULVERIZACION QUE CONTIENEN UN AGENTE ACTIVO DESDE EL PUNTO DE VISTA FARMACEUTICO Y METODOS PARA LA ADMINISTRACION DE LAS MISMAS. LAS FORMULACIONES COMPRENDEN EL AGENTE ACTIVO DESDE EL PUNTO DE VISTA FARMACEUTICO , UN COPOLIMERO DE VP/VA Y UN VEHICULO NO ACUOSO. LAS FORMULACIONES COMPRENDEN ADICIONALMENTE UN AGENTE CONTRA LA NUCLEACION PARA PREVENIR LA RECRISTALIZACION DEL AGENTE ACTIVO DESDE EL PUNTO DE VISTA FARMACEUTICO Y UN INTENSIFICADOR DE LA PENETRACION PARA INCREMENTAR EL INDICE DE ADMINISTRACION DEL FARMACO A TRAVES DE LA PIEL. LUEGO DE LA APLICACION DE LA PIEL, LAS PRESENTES FORMULACIONES SE SECAN PARA PROPORCIONAR UNA PELICULA EN EL SITIO DE TRATAMIENTO
SV2004001916A 2003-10-23 2004-10-22 Formulaciones farmaceuticas transdermales SV2006001916A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1122MU2003 2003-10-23

Publications (1)

Publication Number Publication Date
SV2006001916A true SV2006001916A (es) 2006-03-16

Family

ID=34531861

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2004001916A SV2006001916A (es) 2003-10-23 2004-10-22 Formulaciones farmaceuticas transdermales

Country Status (24)

Country Link
US (1) US20070219171A1 (es)
EP (1) EP1686969A1 (es)
JP (1) JP2007509122A (es)
KR (1) KR20070000397A (es)
CN (1) CN100431531C (es)
AP (1) AP2006003628A0 (es)
AR (1) AR046146A1 (es)
AU (1) AU2004285335B2 (es)
BR (1) BRPI0415725A (es)
CA (1) CA2543245A1 (es)
HK (1) HK1098351A1 (es)
IL (1) IL175094A0 (es)
MA (1) MA28167A1 (es)
MX (1) MXPA06004460A (es)
NO (1) NO20062234L (es)
NZ (1) NZ547376A (es)
PA (1) PA8615501A1 (es)
PE (1) PE20050443A1 (es)
RU (1) RU2006117527A (es)
SM (1) SM200400022B (es)
SV (1) SV2006001916A (es)
TW (1) TW200524635A (es)
WO (1) WO2005041943A1 (es)
ZA (1) ZA200604036B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0518769D0 (en) * 2005-09-14 2005-10-19 Medpharm Ltd Topical formulations
US8481591B2 (en) 2010-11-01 2013-07-09 Stiefel Research Australia Pty. Ltd. Polymeric topical compositions
CN102018671B (zh) * 2011-01-05 2012-07-25 浙江大学 一种雌二醇透皮喷雾剂及其制备方法
US20150065449A1 (en) * 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
TWI516281B (zh) * 2014-07-16 2016-01-11 健維生技有限公司 改良之睪固酮製劑製法及所得之睪固酮製劑
US20170296485A1 (en) 2015-11-23 2017-10-19 Grace Therapeutics Llc Topical Film-Forming Spray
EP3737374B1 (en) * 2018-01-10 2024-04-03 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
US20210236514A1 (en) * 2018-07-05 2021-08-05 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CN112206222A (zh) * 2018-11-09 2021-01-12 北京德默高科医药技术有限公司 含有布洛芬结构类似物的多层经皮给药系统
CN115154661A (zh) * 2022-07-29 2022-10-11 广州莱度品牌管理有限公司 一种仿生角质膜的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72129T1 (de) * 1987-05-27 1992-02-15 Burghart Kurt Transdermal therapeutisch wirkende pharmazeutische zubereitung sowie vorrichtung zum aufbringen der zubereitung.
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
FR2739031B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
NZ513208A (en) * 1999-02-05 2003-05-30 Cipla Ltd Topical sprays comprising a film forming composition
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
US6274167B1 (en) * 2000-09-14 2001-08-14 Vincent Margiotta Topical anesthetic patch
US6528040B1 (en) * 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
DE10211832A1 (de) * 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion

Also Published As

Publication number Publication date
CN1897927A (zh) 2007-01-17
SM200400022A (it) 2005-08-24
CA2543245A1 (en) 2005-05-12
NO20062234L (no) 2006-06-30
EP1686969A1 (en) 2006-08-09
HK1098351A1 (en) 2007-07-20
KR20070000397A (ko) 2007-01-02
AU2004285335A1 (en) 2005-05-12
CN100431531C (zh) 2008-11-12
RU2006117527A (ru) 2007-12-10
PA8615501A1 (es) 2005-10-25
BRPI0415725A (pt) 2006-12-19
AU2004285335B2 (en) 2011-02-10
TW200524635A (en) 2005-08-01
IL175094A0 (en) 2006-08-20
PE20050443A1 (es) 2005-06-14
WO2005041943A1 (en) 2005-05-12
SM200400022B (it) 2005-08-24
NZ547376A (en) 2009-07-31
JP2007509122A (ja) 2007-04-12
ZA200604036B (en) 2007-09-26
MA28167A1 (fr) 2006-09-01
MXPA06004460A (es) 2006-06-27
AR046146A1 (es) 2005-11-23
AP2006003628A0 (en) 2006-06-30
US20070219171A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
PE20081569A1 (es) Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
CR7140A (es) Antranilamidas con una cadena colateral de un heteroarylsulfonil, metodos para la produccion de los mismos, su uso como medicamento o agente diagnostico y preparaciones farmaceuticas contenidas en dichos compuestos
BR112018010234A2 (pt) spray formador de película tópica
SV2006001916A (es) Formulaciones farmaceuticas transdermales
PE20030519A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
ZA202300259B (en) Compound for the treatment of coronaviral infections
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
WO2008114376A1 (ja) メラニン生成抑制組成物
MX2023002671A (es) Formulaciones agradables.
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
BR112022025185A2 (pt) Formas de dosagem osmóticas compreendendo deutetrabenazina e métodos de uso das mesmas
AR045070A1 (es) Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DOP2004001018A (es) Transdermal pharmaceutical formulations
UY28579A1 (es) Formulaciones farmacéuticas transdermicas

Legal Events

Date Code Title Description
FD Lapse